SeptRx Launches PFO Device Trial, Eyeing Mid-2012 CE-Mark Submission
This article was originally published in The Gray Sheet
Executive Summary
Controversy remains over the clinical benefit of using a patent foramen ovale closure device to prevent strokes or other neurological events, but that has not stopped California startup SeptRx from moving ahead with early stage development of its offering.
You may also be interested in...
St. Jude CEO Confident In PFO Device Despite Competitor’s Failure
St. Jude Medical remains confident in its development-stage patent foramen ovale closure device for prevention of strokes or migraines, despite the well publicized failure of competing PFO device developer NMT Medical, CEO Daniel Starks said.
St. Jude CEO Confident In PFO Device Despite Competitor’s Failure
St. Jude Medical remains confident in its development-stage patent foramen ovale closure device for prevention of strokes or migraines, despite the well publicized failure of competing PFO device developer NMT Medical, CEO Daniel Starks said.
News In Brief
Abbott’s RX Acculink